Nasopharyngeal Cancer News and Research

RSS

Chewing tobacco linked to higher stroke and cancer risk, study finds

Chewing tobacco significantly increases the risk of strokes and several types of cancer, revealing critical health implications for its 270 million global users.

7 Feb 2024

BGI cares - 2022 social responsibilities in review

At BGI Genomics, we believe it is our responsibility to not only enhance global health outcomes, but also to help make the places we work and live in better.

From BGI Genomics 20 Dec 2022

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

BGI has currently published over 440 SCI (Science Citation Index) papers in the field of cancer research, with a cumulative impact factor of over 4,000 points.

From BGI Genomics 23 Nov 2022

Research findings could bolster the effectiveness of immune-checkpoint therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.

16 Nov 2022

Cancer drugs work better after vaccination with the Chinese Covid vaccine

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor.

8 Nov 2022

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.

5 Jan 2022

Chinese and Laotian Americans more likely to be diagnosed with nasopharyngeal cancer

Chinese Americans and Laotian Americans were over 10 and 14 times more likely to be diagnosed with nasopharyngeal cancer, respectively, than non-Hispanic white Americans, with incidence rates surpassing other Asian American subgroups, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.

6 Oct 2021

Hi-tech lab taps advanced technology to boost Singapore's future pandemic response

Nanyang Technological University, Singapore (NTU Singapore) and Pathnova Laboratories, a medical diagnostic company backed by Temasek Life Sciences Accelerator and headquartered in Temasek Life Sciences Laboratory, is contributing to Singapore's COVID-19 diagnostic capability through its partnership in a new clinical diagnostic laboratory.

2 Jul 2021

NUS study identifies protein that could be targeted to overcome chemoresistance in cancer

Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cancer cells in the body. It is a systemic treatment where drugs travel throughout the body and destroy cancer cells that have spread (metastasized) to parts of the body far away from the original (primary) tumor.

27 Apr 2021

First comprehensive survey of viruses found within different cancers

Researchers from the University of East Anglia have helped to carry out the first comprehensive survey of viruses found within different types of cancer.

5 Feb 2020

Scientists reveal the structure of a key protein in Epstein-Barr virus infection

Scientists at the Institute for Research in Biomedicine and the Molecular Biology Institute of Barcelona have published a study in the journal Nature Communications revealing the structure of a key protein, known as a portal, in Epstein-Barr virus infection.

29 Aug 2019

Rare Cancers Asia aims to improve patient care

Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients - challenges which are best addressed through collaboration in international networks.

21 Nov 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Virginia lawmakers will convene in a special session next month to address the question of expanding Medicaid and, more broadly, the fact that hundreds of thousands of poor and disabled people in the state have no health insurance coverage. Democrats and some moderate Republicans have advanced a variety of ideas to tackle that problem. Conservative Republicans, who control the legislature in Richmond, have rejected those solutions while proposing no alternative. Does the GOP intend for the special session to be anything more than a charade at taxpayers' expense? (8/15).

19 Aug 2014

Study paves way to develop novel therapies for nasopharyngeal cancer

A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, National University Cancer Institute Singapore (NCIS) and National University Hospital Singapore (NUH), discovered a distinct mutational signature and nine significantly mutated genes associated with nasopharyngeal cancer, paving the way to developing novel therapies for this deadly disease.

23 Jun 2014